Evidence mapPaperPMID 23536133Full record

ArticleKidney international2013

Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes.

Nishant M Bhensdadia, Kelly J Hunt, Maria F Lopes-Virella, J Michael Tucker, Mohammad R Mataria, Joseph L Alge, Benjamin A Neely, Michael G Janech, John M Arthur, Veterans Affairs Diabetes Trial (VADT) study group

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Kidney international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00256646 (CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00256646 completednot on this map

CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes

TypeobservationalSponsorUS Department of Veterans AffairsRan2007 to 2008Enrolled298ConditionsType 2 Diabetes MellitusArmsRosiglitazone
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Novel biomarkers for diabetic kidney disease.Kidney research and clinical practice · 2022
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. The Promise of Systems Biology for Diabetic Kidney Disease.Advances in chronic kidney disease · 2018
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Nishant M BhensdadiaDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Kelly J Hunt
Maria F Lopes-Virella
J Michael Tucker
Mohammad R Mataria
Joseph L Alge
Benjamin A Neely
Michael G Janech
John M Arthur
Veterans Affairs Diabetes Trial (VADT) study group
Medical University of South Carolina · US

Funding

NCRR NIH HHS TL1 RR029881NCRR NIH HHS UL1 RR029882NIDDK NIH HHS R01 DK080234
6 · The paper itself

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease. The urinary albumin to creatinine ratio is used as a predictor for the development of nephropathy but it is neither sensitive nor specific. Here we used liquid chromatography/mass spectrometry on urine of eight normoalbuminuric patients with type 2 diabetes from the VA Diabetes Trial to identify candidate markers for loss of renal function. Initial verification of seven markers (agrin, haptoglobin, mannan-binding lectin serine protease 2, LAMP-2, angiotensinogen, NGAL, and uromodulin) in the urine of an additional 30 patients showed that haptoglobin was the best predictor of early renal functional decline. We then measured this in the urine of 204 patients with type 2 diabetes who did not yet have significant kidney disease (estimated glomerular filtration rate stage 2 or better and an albumin to creatinine ratio <300 mg/g). In comparing the highest to lowest tertiles, the odds ratio for having early renal function decline was 2.70 (CI: 1.15, 6.32) using the haptoglobin to creatinine ratio compared with 2.50 (CI 1.14, 5.48) using the albumin to creatinine ratio after adjusting for treatment group and use of ACE inhibitors. Addition of the haptoglobin to creatinine ratio to a model using the albumin to creatinine ratio to predict early renal function decline resulted in improved predictive performance. Thus, the haptoglobin to creatinine ratio may be useful to predict patients with type 2 diabetes at risk of nephropathy before the development of macroalbuminuria or reduced glomerular filtration rate.

Indexed as

AlbuminuriaBiomarkersChi-Square DistributionChromatography, LiquidCreatinineDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleGlomerular Filtration RateHaptoglobinsHumansKidneyLogistic ModelsMaleMass SpectrometryBiomarkersCreatinineHaptoglobinsHP protein, human

Identifiers

PMID23536133
PMCPMC3672380
OpenAlexW2101761968

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.